Physician profile
Joy Bloch
NPI 1740363167
$2,650.13
in general payments reported to CMS, 2019-2025
25 companies · $852 in 2025
The $852 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $117 · 2022: $15.10 · 2023: $511 · 2024: $734 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $393.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $366.74 | 2019-2025 | Cobenfy, Eliquis |
| Pfizer INC. | $287.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $204.75 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $166.42 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $159.97 | 2019-2025 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.00 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.41 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $103.57 | 2023-2025 | |
| Astellas Pharma US INC | $102.06 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $78.82 | 2019-2025 | Capvaxive, Gardasil 9, Belsomra |
| Exact Sciences Corporation | $71.89 | 2023-2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $64.15 | 2023-2025 | Heplisav-B |
| Amarin Pharma, INC. | $57.66 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $55.33 | 2019-2024 | Xarelto |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $51.12 | 2025 | Pyrukynd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.57 | 2023-2025 | Xifaxan |
| Abbvie INC. | $42.37 | 2025 | |
| Sanofi-Aventis U.S. LLC | $30.21 | 2025 | |
| Amgen INC. | $20.87 | 2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $20.30 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $19.99 | 2025 | |
| Sanofi Pasteur INC. | $19.62 | 2019 | |
| Inspire Medical Systems, INC. | $18.29 | 2025 | Inspire |
| Boston Scientific Corporation | $15.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Bloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.